{"transactions":[{"id":4633514,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-30T20:35:28.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 3,992 shares of previously-granted restricted stock units subject to vesting requirements."}],"balance_after":19293.926,"source":{"system":"sec-edgar","filing":"0001071739-26-000180","document":"wk-form4_1790800525.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173926000180/wk-form4_1790800525.xml","form_type":"4"}},{"id":721827,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-01T21:47:07.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 3,992 shares of restricted stock units subject to vesting requirements."}],"balance_after":18710.926,"source":{"system":"sec-edgar","filing":"0001071739-26-000140","document":"wk-form4_1782942424.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173926000140/wk-form4_1782942424.xml","form_type":"4"}},{"id":781331,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-13T21:17:35.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":3992,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This award includes 3,992 shares of restricted stock units which will vest in full on the earlier of May 12, 2027, or the date of the Registrant's next annual meeting of stockholders."}],"balance_after":18148.926,"source":{"system":"sec-edgar","filing":"0001071739-26-000110","document":"wk-form4_1778707052.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173926000110/wk-form4_1778707052.xml","form_type":"4"}},{"id":824519,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-31T22:01:59.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":1140,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 3,579 shares of restricted stock units subject to vesting requirements."}],"balance_after":14156.926,"source":{"system":"sec-edgar","filing":"0001071739-26-000086","document":"wk-form4_1774994516.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173926000086/wk-form4_1774994516.xml","form_type":"4"}},{"id":953045,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-05T21:55:30.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":729,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 3,579 shares of restricted stock units subject to vesting requirements."}],"balance_after":13016.926,"source":{"system":"sec-edgar","filing":"0001071739-26-000005","document":"wk-form4_1767650127.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173926000005/wk-form4_1767650127.xml","form_type":"4"}},{"id":1029786,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-01T21:46:53.000Z","date":"2025-09-30","kind":"grant","planned":false,"acquired":true,"shares":852,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 3,579 shares of restricted stock units subject to vesting requirements."}],"balance_after":12287.926,"source":{"system":"sec-edgar","filing":"0001071739-25-000175","document":"wk-form4_1759355210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173925000175/wk-form4_1759355210.xml","form_type":"4"}},{"id":1096207,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T20:58:25.000Z","date":"2025-06-30","kind":"grant","planned":false,"acquired":true,"shares":556,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 3,579 shares of restricted stock units subject to vesting requirements."}],"balance_after":11435.926,"source":{"system":"sec-edgar","filing":"0001071739-25-000141","document":"wk-form4_1751489897.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173925000141/wk-form4_1751489897.xml","form_type":"4"}},{"id":1149766,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-14T21:23:22.000Z","date":"2025-05-13","kind":"grant","planned":false,"acquired":true,"shares":3579,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This award includes 3,579 shares of restricted stock units which will vest in full on the earlier of May 13, 2026, or the date of the Registrant's next annual meeting of stockholders."}],"balance_after":10879.926,"source":{"system":"sec-edgar","filing":"0001071739-25-000110","document":"wk-form4_1747257793.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173925000110/wk-form4_1747257793.xml","form_type":"4"}},{"id":1184488,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-02T21:07:49.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 2,916 shares of restricted stock units subject to vesting requirements."}],"balance_after":7300.926,"source":{"system":"sec-edgar","filing":"0001071739-25-000076","document":"wk-form4_1743628060.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173925000076/wk-form4_1743628060.xml","form_type":"4"}},{"id":1316251,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-03T21:52:52.000Z","date":"2024-12-31","kind":"grant","planned":false,"acquired":true,"shares":497,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 2,916 shares of restricted stock units subject to vesting requirements."}],"balance_after":6800.926,"source":{"system":"sec-edgar","filing":"0001071739-25-000007","document":"wk-form4_1735941166.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173925000007/wk-form4_1735941166.xml","form_type":"4"}},{"id":1329635,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-18T00:33:45.000Z","date":"2024-12-16","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":59.44,"value":594400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average price for this transaction is reported within the form. Shares were purchased at prices ranging from $59.43 to $59.44. Full information regarding the number of shares at each price is available upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Ownership includes 2,916 shares of restricted stock units subject to vesting requirements."}],"balance_after":36357.926,"source":{"system":"sec-edgar","filing":"0001071739-24-000227","document":"wk-form4_1734482019.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173924000227/wk-form4_1734482019.xml","form_type":"4"}},{"id":1395237,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-02T21:11:32.000Z","date":"2024-09-30","kind":"grant","planned":false,"acquired":true,"shares":402,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 2,916 shares of restricted stock units subject to vesting requirements."}],"balance_after":26357.926,"source":{"system":"sec-edgar","filing":"0001071739-24-000182","document":"wk-form4_1727903484.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173924000182/wk-form4_1727903484.xml","form_type":"4"}},{"id":1463910,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-02T21:35:27.000Z","date":"2024-06-30","kind":"grant","planned":false,"acquired":true,"shares":452,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 2,916 shares of restricted stock units subject to vesting requirements."}],"balance_after":25955.926,"source":{"system":"sec-edgar","filing":"0001071739-24-000144","document":"wk-form4_1719956122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173924000144/wk-form4_1719956122.xml","form_type":"4"}},{"id":1502444,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-24T21:28:47.000Z","date":"2024-05-14","kind":"sale","planned":false,"acquired":false,"shares":878,"price":76.745,"value":67382.11,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Owned by family trusts, of which Mr. Coughlin serves as the sole trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001071739-24-000128","document":"wk-form4_1716586116.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173924000128/wk-form4_1716586116.xml","form_type":"4"}},{"id":1514807,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-16T22:13:47.000Z","date":"2024-05-14","kind":"grant","planned":false,"acquired":true,"shares":2916,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This award includes  2,916 shares of restricted stock units which will vest in full on the earlier of May 14, 2025, and the date of the Registrant's next annual meeting of stockholders."}],"balance_after":25503.926,"source":{"system":"sec-edgar","filing":"0001071739-24-000118","document":"wk-form4_1715897603.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173924000118/wk-form4_1715897603.xml","form_type":"4"}},{"id":1554503,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-02T23:36:59.000Z","date":"2024-03-31","kind":"grant","planned":false,"acquired":true,"shares":388.551,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 2,947 shares of restricted stock subject to vesting requirements."}],"balance_after":22587.926,"source":{"system":"sec-edgar","filing":"0001071739-24-000087","document":"wk-form4_1712101007.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173924000087/wk-form4_1712101007.xml","form_type":"4"}},{"id":1572921,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:46.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1904,"price":92.3,"value":175739.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date."}],"balance_after":0,"derivative":{"exercise_price":237.7,"expiration_date":"2033-06-19","underlying":"Common Stock","underlying_shares":1904},"source":{"system":"sec-edgar","filing":"0001140361-24-013924","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000114036124013924/form4.xml","form_type":"4"}},{"id":1572920,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:46.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":976,"price":136.81,"value":133526.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":193.19,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":976},"source":{"system":"sec-edgar","filing":"0001140361-24-013924","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000114036124013924/form4.xml","form_type":"4"}},{"id":1572919,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:46.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"price":227.04,"value":1135200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":102.96,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001140361-24-013924","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000114036124013924/form4.xml","form_type":"4"}},{"id":1572918,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:46.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8500,"price":201.99,"value":1716915.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":128.01,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001140361-24-013924","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000114036124013924/form4.xml","form_type":"4"}},{"id":1572917,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true}}],"security":"Option (right to buy)","published_at":"2024-03-18T20:30:46.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"price":243.35,"value":6083750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the \"Options\"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Options are fully vested."}],"balance_after":0,"derivative":{"exercise_price":86.65,"expiration_date":"2030-04-23","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001140361-24-013924","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000114036124013924/form4.xml","form_type":"4"}},{"id":1572916,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-18T20:30:46.000Z","date":"2024-03-18","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":990,"price":330,"value":326700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2024, Bristol-Myers Squibb Company (\"Bristol-Myers\") acquired Karuna Therapeutics, Inc. (the \"Issuer\") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the \"Merger Agreement\"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the \"Common Stock\") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-24-013924","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000114036124013924/form4.xml","form_type":"4"}},{"id":1693956,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-03T23:29:24.000Z","date":"2023-12-31","kind":"grant","planned":false,"acquired":true,"shares":502.495,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 2,947 shares of restricted stock subject to vesting requirements."}],"balance_after":22199.375,"source":{"system":"sec-edgar","filing":"0001071739-24-000007","document":"wk-form4_1704324553.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173924000007/wk-form4_1704324553.xml","form_type":"4"}},{"id":1768527,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-03T22:51:09.000Z","date":"2023-09-30","kind":"grant","planned":false,"acquired":true,"shares":544.867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 2,947 shares of restricted stock subject to vesting requirements."}],"balance_after":21696.88,"source":{"system":"sec-edgar","filing":"0001071739-23-000197","document":"wk-form4_1696373460.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173923000197/wk-form4_1696373460.xml","form_type":"4"}},{"id":1837416,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-05T23:39:05.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":543.56,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 2,947 shares of restricted stock units subject to vesting requirements."}],"balance_after":21152.013,"source":{"system":"sec-edgar","filing":"0001071739-23-000172","document":"wk-form4_1688600336.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173923000172/wk-form4_1688600336.xml","form_type":"4"}},{"id":1846814,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-06-22T20:11:26.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":1904,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates."}],"balance_after":1904,"derivative":{"exercise_price":237.7,"expiration_date":"2033-06-19","underlying":"Common Stock","underlying_shares":1904},"source":{"system":"sec-edgar","filing":"0000950170-23-029407","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000095017023029407/ownership.xml","form_type":"4"}},{"id":1846813,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-22T20:11:26.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Comprised of restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates."}],"balance_after":990,"source":{"system":"sec-edgar","filing":"0000950170-23-029407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000095017023029407/ownership.xml","form_type":"4"}},{"id":1895544,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-12T22:20:15.000Z","date":"2023-05-10","kind":"grant","planned":false,"acquired":true,"shares":2947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 2,947 shares of restricted stock which will vest in full on the earlier of May 10, 2024 and the date of the Registrant's next annual meeting of stockholders."}],"balance_after":20608.453,"source":{"system":"sec-edgar","filing":"0001071739-23-000137","document":"wf-form4_168393000475043.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173923000137/wf-form4_168393000475043.xml","form_type":"4"}},{"id":1929699,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-05T01:15:42.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":510.635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 2,323 shares of restricted stock units subject to vesting requirements."}],"balance_after":17661.453,"source":{"system":"sec-edgar","filing":"0001071739-23-000100","document":"wf-form4_168065733150263.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173923000100/wf-form4_168065733150263.xml","form_type":"4"}},{"id":2063352,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-01-05T21:45:31.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":181,"price":110.5,"value":20000.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees for board services in 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as to 25% of the shares underlying the option award on each three month anniversary following the vesting commencement date of January 3, 2023."}],"balance_after":181,"derivative":{"exercise_price":193.19,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":181},"source":{"system":"sec-edgar","filing":"0001593968-23-000080","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000159396823000080/primary_01.xml","form_type":"4"}},{"id":2063351,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-01-05T21:45:31.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":67,"price":111.94,"value":7499.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees for board services in 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as to 25% of the shares underlying the option award on each three month anniversary following the vesting commencement date of January 3, 2023."}],"balance_after":67,"derivative":{"exercise_price":193.19,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":67},"source":{"system":"sec-edgar","filing":"0001593968-23-000080","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000159396823000080/primary_01.xml","form_type":"4"}},{"id":2063350,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-01-05T21:45:31.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":407,"price":110.57,"value":45001.99,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees for board services in 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as to 25% of the shares underlying the option award on each three month anniversary following the vesting commencement date of January 3, 2023."}],"balance_after":407,"derivative":{"exercise_price":193.19,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":407},"source":{"system":"sec-edgar","filing":"0001593968-23-000080","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000159396823000080/primary_01.xml","form_type":"4"}},{"id":2063349,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-01-05T21:45:31.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":321,"price":110.41,"value":35441.61,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees for board services in 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests as to 25% of the shares underlying the option award on each three month anniversary following the vesting commencement date of January 3, 2023."}],"balance_after":321,"derivative":{"exercise_price":193.19,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":321},"source":{"system":"sec-edgar","filing":"0001593968-23-000080","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000159396823000080/primary_01.xml","form_type":"4"}},{"id":2069483,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-05T00:06:55.000Z","date":"2022-12-31","kind":"grant","acquired":true,"shares":443.805,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 2,323 shares of restricted stock units subject to vesting requirements."}],"balance_after":17150.818,"source":{"system":"sec-edgar","filing":"0001071739-23-000012","document":"wf-form4_167287719929148.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173923000012/wf-form4_167287719929148.xml","form_type":"4"}},{"id":2145622,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-05T01:18:45.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":405.617,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 2,323 shares of restricted stock units subject to vesting requirements."}],"balance_after":16707.013,"source":{"system":"sec-edgar","filing":"0001071739-22-000346","document":"wf-form4_166493209167142.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173922000346/wf-form4_166493209167142.xml","form_type":"4"}},{"id":2196161,"issuer":{"id":4350,"kind":"organization","name":"Prestige Consumer Healthcare Inc."},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.01 per share","published_at":"2022-08-03T21:19:25.000Z","date":"2022-08-02","kind":"grant","acquired":true,"shares":2495,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received 2,495 restricted stock units (equal to $150,000 divided by the closing stock price of $60.12on August 2, 2022) in connection with the Issuer's director compensation program. The restricted stock units vest on August 2, 2023."}],"balance_after":13218,"source":{"system":"sec-edgar","filing":"0001104659-22-085713","document":"tm2222537-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000110465922085713/tm2222537-5_4seq1.xml","form_type":"4"}},{"id":2215435,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-05T23:47:51.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":436.431,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 2,323 shares of restricted stock units subject to vesting requirements."}],"balance_after":16301.396,"source":{"system":"sec-edgar","filing":"0001071739-22-000265","document":"wf-form4_165706485739158.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173922000265/wf-form4_165706485739158.xml","form_type":"4"}},{"id":2230374,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-06-16T20:31:02.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 15, 2023, and (ii) the 2023 annual meeting of the Issuer's stockholders."}],"balance_after":5000,"derivative":{"exercise_price":102.96,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001593968-22-001147","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000159396822001147/primary_01.xml","form_type":"4"}},{"id":2284995,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-03T23:12:14.000Z","date":"2022-04-29","kind":"purchase","acquired":true,"shares":12000,"price":81.37,"value":976440.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average price for this transaction is reported within the form. Shares were sold at prices ranging from $81.34 to $81.37. Full information regarding the number of shares at each price is available upon request"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Ownership includes 2,323 shares of restricted stock units subject to vesting requirements."}],"balance_after":15864.965,"source":{"system":"sec-edgar","filing":"0001071739-22-000219","document":"wf-form4_165161949758074.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173922000219/wf-form4_165161949758074.xml","form_type":"4"}},{"id":2288943,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T01:01:53.000Z","date":"2022-04-26","kind":"grant","acquired":true,"shares":2323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 2,323 shares of restricted stock which will vest in full on the earlier of April 26, 2023 and the date of the Registrant's next annual meeting of stockholders."}],"balance_after":3864.965,"source":{"system":"sec-edgar","filing":"0001071739-22-000199","document":"wf-form4_165119398351804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173922000199/wf-form4_165119398351804.xml","form_type":"4"}},{"id":2309215,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T00:40:57.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":441.965,"price":82.02,"value":36249.9693,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 1,100 shares of restricted stock units subject to vesting requirements."}],"balance_after":1541.965,"source":{"system":"sec-edgar","filing":"0001071739-22-000148","document":"wf-form4_164911923713237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173922000148/wf-form4_164911923713237.xml","form_type":"4"}},{"id":2406863,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Option (right to buy)","published_at":"2022-02-10T00:35:11.000Z","date":"2022-02-07","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in three equal installments on the anniversary of the grant beginning on February 7, 2023."}],"balance_after":10000,"derivative":{"exercise_price":80.57,"exercise_date":"2025-02-07","expiration_date":"2032-02-07","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001071739-22-000061","document":"wf-form4_164445329459039.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173922000061/wf-form4_164445329459039.xml","form_type":"4"}},{"id":2406862,"issuer":{"id":3133,"kind":"organization","name":"CENTENE CORP","symbol":"CNC"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-10T00:35:11.000Z","date":"2022-02-07","kind":"grant","acquired":true,"shares":1100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Ownership includes 1,100 shares of restricted stock vesting on the date of the April 2022 Annual Meeting of Stockholders."}],"balance_after":1100,"source":{"system":"sec-edgar","filing":"0001071739-22-000061","document":"wf-form4_164445329459039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173922000061/wf-form4_164445329459039.xml","form_type":"4"}},{"id":2613369,"issuer":{"id":4350,"kind":"organization","name":"Prestige Consumer Healthcare Inc."},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.01 per share","published_at":"2021-08-05T23:03:23.000Z","date":"2021-08-03","kind":"grant","acquired":true,"shares":2808,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received 2,808 restricted stock units (equal to $150,000 divided by the closing stock price of $53.42 on August 3, 2021) in connection with the Issuer's director compensation program. The restricted stock units vest immediately upon grant and will be settled by delivery to the Reporting Person of one share of common stock of the Issuer for each vested restricted stock unit promptly following the earliest of (i) the Reporting Person's death, (ii) the Reporting Person's separation from service or (iii) change in control."}],"balance_after":10723,"source":{"system":"sec-edgar","filing":"0001104659-21-100938","document":"tm2124298-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000110465921100938/tm2124298-1_4seq1.xml","form_type":"4"}},{"id":2626570,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-07-23T16:54:11.000Z","date":"2021-07-21","kind":"disposition_to_issuer","acquired":false,"shares":2343,"price":155.01,"value":363188.43,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":155.01,"exercise_date":"2016-05-06","expiration_date":"2025-05-06","underlying":"Common Stock, par value $.0001 per share","underlying_shares":2343},"source":{"system":"sec-edgar","filing":"0000899866-21-000077","document":"wf-form4_162707363692831.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986621000077/wf-form4_162707363692831.xml","form_type":"4"}},{"id":2626569,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-07-23T16:54:11.000Z","date":"2021-07-21","kind":"disposition_to_issuer","acquired":false,"shares":2706,"price":167.97,"value":454526.82,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":167.97,"exercise_date":"2015-07-22","expiration_date":"2024-07-22","underlying":"Common Stock, par value $.0001 per share","underlying_shares":2706},"source":{"system":"sec-edgar","filing":"0000899866-21-000077","document":"wf-form4_162707363692831.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986621000077/wf-form4_162707363692831.xml","form_type":"4"}},{"id":2626568,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-07-23T16:54:11.000Z","date":"2021-07-21","kind":"disposition_to_issuer","acquired":false,"shares":2294,"price":138.86,"value":318544.84,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":138.86,"exercise_date":"2017-05-11","expiration_date":"2026-05-11","underlying":"Common Stock, par value $.0001 per share","underlying_shares":2294},"source":{"system":"sec-edgar","filing":"0000899866-21-000077","document":"wf-form4_162707363692831.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986621000077/wf-form4_162707363692831.xml","form_type":"4"}},{"id":2626567,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2021-07-23T16:54:11.000Z","date":"2021-07-21","kind":"disposition_to_issuer","acquired":false,"shares":42347,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the \"Merger Consideration\").  Upon the First Effective Time, 2,495 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899866-21-000077","document":"wf-form4_162707363692831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986621000077/wf-form4_162707363692831.xml","form_type":"4"}},{"id":2657658,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2021-06-23T20:29:27.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 16, 2022, and (ii) the 2022 annual meeting of the Issuer's stockholders."}],"balance_after":8500,"derivative":{"exercise_price":128.01,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001593968-21-001681","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000159396821001681/primary_01.xml","form_type":"4"}},{"id":2699686,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2021-05-24T16:36:17.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":729,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest as to 25% on a quarterly basis. These Restricted Stock Units were issued in lieu ofthe annual cash retainer that the director was entitled to receive for service as a director."}],"balance_after":42347,"source":{"system":"sec-edgar","filing":"0000899866-21-000047","document":"wf-form4_162188855020732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986621000047/wf-form4_162188855020732.xml","form_type":"4"}},{"id":2699685,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2021-05-24T16:36:17.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":1962,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest in their entirety on the first anniversary of the grant date."}],"balance_after":41618,"source":{"system":"sec-edgar","filing":"0000899866-21-000047","document":"wf-form4_162188855020732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986621000047/wf-form4_162188855020732.xml","form_type":"4"}},{"id":3066115,"issuer":{"id":4350,"kind":"organization","name":"Prestige Consumer Healthcare Inc."},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.01 per share","published_at":"2020-08-06T21:23:28.000Z","date":"2020-08-04","kind":"grant","acquired":true,"shares":3732,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received 3,732 restricted stock units (equal to $145,000 divided by the closing stock price of $38.86 on August 4, 2020) in connection with the Issuer's director compensation program. The restricted stock units vest immediately upon grant and will be settled by delivery to the Reporting Person of one share of common stock of the Issuer for each vested restricted stock unit promptly following the earliest of (i) the Reporting Person's death, (ii) the Reporting Person's separation from service or (iii) change in control."}],"balance_after":7915,"source":{"system":"sec-edgar","filing":"0001104659-20-091547","document":"tm2023357d4_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000110465920091547/tm2023357d4_4.xml","form_type":"4"}},{"id":3146177,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2020-05-18T17:15:43.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":2774,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest as to 25% on a quarterly basis. These Restricted Stock Units were issued in lieu of the annual cash retainer that the director was entitled to receive for service as a director."}],"balance_after":39656,"source":{"system":"sec-edgar","filing":"0000899866-20-000046","document":"wf-form4_158983652588830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986620000046/wf-form4_158983652588830.xml","form_type":"4"}},{"id":3146176,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2020-05-18T17:15:43.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":3468,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest in their entirety on the earlier of (i) the first anniversary of the grant date and (ii) the date of the 2021 Annual Shareholder Meeting."}],"balance_after":36882,"source":{"system":"sec-edgar","filing":"0000899866-20-000046","document":"wf-form4_158983652588830.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986620000046/wf-form4_158983652588830.xml","form_type":"4"}},{"id":3154826,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2020-05-12T01:34:00.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":9446,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":70.79,"expiration_date":"2021-08-22","underlying":"Ordinary Shares","underlying_shares":9446},"source":{"system":"sec-edgar","filing":"0000899243-20-012725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000089924320012725/doc4.xml","form_type":"4"}},{"id":3154825,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2020-05-12T01:34:00.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":3691,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":73.14,"expiration_date":"2022-08-22","underlying":"Ordinary Shares","underlying_shares":3691},"source":{"system":"sec-edgar","filing":"0000899243-20-012725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000089924320012725/doc4.xml","form_type":"4"}},{"id":3154824,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2020-05-12T01:34:00.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":2790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":90.22,"expiration_date":"2023-08-14","underlying":"Ordinary Shares","underlying_shares":2790},"source":{"system":"sec-edgar","filing":"0000899243-20-012725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000089924320012725/doc4.xml","form_type":"4"}},{"id":3154823,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2020-05-12T01:34:00.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":16532,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects the disposition of ordinary shares (\"Allergan Shares\") of Allergan plc (\"Allergan\") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. (\"AbbVie\"), Venice Subsidiary, LLC (\"Acquirer Sub\") and Allergan (the \"Transaction Agreement\"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the \"Scheme\").  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-012725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000089924320012725/doc4.xml","form_type":"4"}},{"id":3154822,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2020-05-12T01:34:00.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":9538,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By family trust"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects the disposition of ordinary shares (\"Allergan Shares\") of Allergan plc (\"Allergan\") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. (\"AbbVie\"), Venice Subsidiary, LLC (\"Acquirer Sub\") and Allergan (the \"Transaction Agreement\"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the \"Scheme\").  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share."}],"balance_after":16542,"source":{"system":"sec-edgar","filing":"0000899243-20-012725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000089924320012725/doc4.xml","form_type":"4"}},{"id":3154821,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2020-05-12T01:34:00.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":471,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By grantor retained annuity trust"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects the disposition of ordinary shares (\"Allergan Shares\") of Allergan plc (\"Allergan\") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. (\"AbbVie\"), Venice Subsidiary, LLC (\"Acquirer Sub\") and Allergan (the \"Transaction Agreement\"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the \"Scheme\").  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share."}],"balance_after":26080,"source":{"system":"sec-edgar","filing":"0000899243-20-012725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000089924320012725/doc4.xml","form_type":"4"}},{"id":3163921,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2020-05-05T01:00:57.000Z","date":"2020-05-01","kind":"tax_withholding","acquired":false,"shares":991,"price":189.74,"value":188032.34,"ownership":{"direct":true},"balance_after":16542,"source":{"system":"sec-edgar","filing":"0001179110-20-005451","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911020005451/edgar.xml","form_type":"4"}},{"id":3168419,"issuer":{"id":92934,"kind":"organization","name":"Karuna Therapeutics, Inc.","symbol":"KRTX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2020-04-28T21:03:00.000Z","date":"2020-04-24","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in thirty-six equal monthly installments beginning on May 24, 2020."}],"balance_after":25000,"derivative":{"exercise_price":86.65,"expiration_date":"2030-04-23","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001593968-20-001055","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000159396820001055/primary_01.xml","form_type":"4"}},{"id":3274718,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2020-02-13T22:12:14.000Z","date":"2019-06-18","kind":"gift","acquired":false,"shares":9538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":12776,"source":{"system":"sec-edgar","filing":"0001179110-20-001568","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911020001568/edgar.xml","form_type":"5"}},{"id":3451109,"issuer":{"id":4350,"kind":"organization","name":"Prestige Consumer Healthcare Inc."},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.01 per share","published_at":"2019-08-01T20:32:33.000Z","date":"2019-07-30","kind":"grant","acquired":true,"shares":4183,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received 4,183 restricted stock units (equal to $145,000 divided by the closing stock price of $34.67 on July 30, 2019) in connection with the Issuer's director compensation program. The restricted stock units vest immediately upon grant and will be settled by delivery to the Reporting Person of one share of common stock of the Issuer for each vested restricted stock unit promptly following the earliest of (i) the Reporting Person's death, (ii) the Reporting Person's separation from service or (iii)  change in control."}],"balance_after":4183,"source":{"system":"sec-edgar","filing":"0001144204-19-037223","document":"tv526535_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000114420419037223/tv526535_4.xml","form_type":"4"}},{"id":3522260,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2019-05-17T16:30:34.000Z","date":"2019-05-15","kind":"grant","acquired":true,"shares":2181,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest as to 25% on a quarterly basis. These Restricted Stock Units were issued in lieu of the annual cash retainer that the director was entitled to receive for service as a director."}],"balance_after":33414,"source":{"system":"sec-edgar","filing":"0000899866-19-000067","document":"wf-form4_155812501882400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986619000067/wf-form4_155812501882400.xml","form_type":"4"}},{"id":3522259,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2019-05-17T16:30:34.000Z","date":"2019-05-15","kind":"grant","acquired":true,"shares":2726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units under the 2017 Incentive Plan. Shares issuable pursuant to the Restricted Stock Units vest in their entirety on the first anniversary of the grant date."}],"balance_after":31233,"source":{"system":"sec-edgar","filing":"0000899866-19-000067","document":"wf-form4_155812501882400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986619000067/wf-form4_155812501882400.xml","form_type":"4"}},{"id":3542553,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2019-05-03T00:46:49.000Z","date":"2019-05-02","kind":"grant","acquired":true,"shares":2064,"price":145.33,"value":299961.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These restricted stock units shall vest 100% on the earlier of (i) the day before the 2020 Annual General Meeting of Shareholders and (ii) May 1, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":17080,"source":{"system":"sec-edgar","filing":"0001179110-19-005489","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911019005489/edgar.xml","form_type":"4"}},{"id":3542552,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2019-05-03T00:46:49.000Z","date":"2019-04-30","kind":"tax_withholding","acquired":false,"shares":953,"price":147,"value":140091.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":15016,"source":{"system":"sec-edgar","filing":"0001179110-19-005489","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911019005489/edgar.xml","form_type":"4"}},{"id":3822419,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-09-07T12:31:17.000Z","date":"2018-09-06","kind":"purchase","acquired":true,"shares":300,"price":190.63,"value":57189.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":16431,"source":{"system":"sec-edgar","filing":"0001179110-18-011184","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911018011184/edgar.xml","form_type":"4"}},{"id":3822418,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-09-07T12:31:17.000Z","date":"2018-09-06","kind":"purchase","acquired":true,"shares":517,"price":190.64,"value":98560.88,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":16131,"source":{"system":"sec-edgar","filing":"0001179110-18-011184","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911018011184/edgar.xml","form_type":"4"}},{"id":3822417,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-09-07T12:31:17.000Z","date":"2018-09-06","kind":"purchase","acquired":true,"shares":4889,"price":190.68,"value":932234.52,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":15614,"source":{"system":"sec-edgar","filing":"0001179110-18-011184","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911018011184/edgar.xml","form_type":"4"}},{"id":3822416,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-09-07T12:31:17.000Z","date":"2018-09-06","kind":"purchase","acquired":true,"shares":222,"price":190.67,"value":42328.74,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":10725,"source":{"system":"sec-edgar","filing":"0001179110-18-011184","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911018011184/edgar.xml","form_type":"4"}},{"id":3822415,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-09-07T12:31:17.000Z","date":"2018-09-06","kind":"purchase","acquired":true,"shares":816,"price":190.66,"value":155578.56,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":10503,"source":{"system":"sec-edgar","filing":"0001179110-18-011184","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911018011184/edgar.xml","form_type":"4"}},{"id":3822414,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-09-07T12:31:17.000Z","date":"2018-09-06","kind":"purchase","acquired":true,"shares":100,"price":190.65,"value":19065.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":9687,"source":{"system":"sec-edgar","filing":"0001179110-18-011184","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911018011184/edgar.xml","form_type":"4"}},{"id":3822413,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-09-07T12:31:17.000Z","date":"2018-09-06","kind":"purchase","acquired":true,"shares":68,"price":190.62,"value":12962.16,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":9587,"source":{"system":"sec-edgar","filing":"0001179110-18-011184","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911018011184/edgar.xml","form_type":"4"}},{"id":3822412,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-09-07T12:31:17.000Z","date":"2018-09-06","kind":"purchase","acquired":true,"shares":200,"price":190.61,"value":38122.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":9519,"source":{"system":"sec-edgar","filing":"0001179110-18-011184","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911018011184/edgar.xml","form_type":"4"}},{"id":3822411,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-09-07T12:31:17.000Z","date":"2018-09-06","kind":"purchase","acquired":true,"shares":400,"price":190.6,"value":76240.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":9319,"source":{"system":"sec-edgar","filing":"0001179110-18-011184","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911018011184/edgar.xml","form_type":"4"}},{"id":3822410,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-09-07T12:31:17.000Z","date":"2018-09-06","kind":"purchase","acquired":true,"shares":356,"price":190.59,"value":67850.04,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":8919,"source":{"system":"sec-edgar","filing":"0001179110-18-011184","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911018011184/edgar.xml","form_type":"4"}},{"id":3822409,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-09-07T12:31:17.000Z","date":"2018-09-06","kind":"purchase","acquired":true,"shares":100,"price":190.58,"value":19058.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":8563,"source":{"system":"sec-edgar","filing":"0001179110-18-011184","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911018011184/edgar.xml","form_type":"4"}},{"id":3822408,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-09-07T12:31:17.000Z","date":"2018-09-06","kind":"purchase","acquired":true,"shares":27,"price":190.57,"value":5145.39,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":8463,"source":{"system":"sec-edgar","filing":"0001179110-18-011184","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911018011184/edgar.xml","form_type":"4"}},{"id":3822407,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-09-07T12:31:17.000Z","date":"2018-09-06","kind":"purchase","acquired":true,"shares":705,"price":190.56,"value":134344.8,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":8436,"source":{"system":"sec-edgar","filing":"0001179110-18-011184","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911018011184/edgar.xml","form_type":"4"}},{"id":3822406,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-09-07T12:31:17.000Z","date":"2018-09-06","kind":"purchase","acquired":true,"shares":1300,"price":190.55,"value":247715.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":7731,"source":{"system":"sec-edgar","filing":"0001179110-18-011184","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911018011184/edgar.xml","form_type":"4"}},{"id":3937740,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2018-05-11T16:14:11.000Z","date":"2018-05-09","kind":"grant","acquired":true,"shares":2174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units under the 2017 Incentive Plan. Award vests on the anniversary of the grant date."}],"balance_after":28507,"source":{"system":"sec-edgar","filing":"0000899866-18-000094","document":"wf-form4_152606963807051.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986618000094/wf-form4_152606963807051.xml","form_type":"4"}},{"id":3945753,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-05-04T22:22:42.000Z","date":"2018-05-02","kind":"grant","acquired":true,"shares":1985,"price":151.07,"value":299873.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These restricted stock units shall vest 100% on the earlier of (i) the day before the 2019 Annual General Meeting of Shareholders and (ii) May 2, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":6431,"source":{"system":"sec-edgar","filing":"0001179110-18-006356","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911018006356/edgar.xml","form_type":"4"}},{"id":3945752,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-05-04T22:22:42.000Z","date":"2018-02-28","kind":"gift","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a transfer to a grantor retained annuity trust for which the reporting person is the trustee and sole annuitant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":4446,"source":{"system":"sec-edgar","filing":"0001179110-18-006356","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911018006356/edgar.xml","form_type":"4"}},{"id":3950278,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2018-05-02T17:42:44.000Z","date":"2018-04-30","kind":"purchase","acquired":true,"shares":10000,"price":120.79,"value":1207900.0,"ownership":{"direct":true},"balance_after":26333,"source":{"system":"sec-edgar","filing":"0000899866-18-000078","document":"wf-form4_152529735154605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986618000078/wf-form4_152529735154605.xml","form_type":"4"}},{"id":4142492,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-12-05T21:16:09.000Z","date":"2017-12-05","kind":"purchase","acquired":true,"shares":10000,"price":163.3,"value":1633000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":14446,"source":{"system":"sec-edgar","filing":"0001179110-17-014905","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911017014905/edgar.xml","form_type":"4"}},{"id":4143147,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-12-05T18:05:01.000Z","date":"2017-12-05","kind":"grant","acquired":true,"shares":10000,"price":112.75,"value":1127500.0,"ownership":{"direct":true},"balance_after":16333,"source":{"system":"sec-edgar","filing":"0000899866-17-000184","document":"wf-form4_151251508712742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000184/wf-form4_151251508712742.xml","form_type":"4"}},{"id":4279745,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-06-16T16:55:00.000Z","date":"2017-06-15","kind":"purchase","acquired":true,"shares":2000,"price":117.1,"value":234200.0,"ownership":{"direct":true},"balance_after":6333,"source":{"system":"sec-edgar","filing":"0000899866-17-000143","document":"wf-form4_149764648587584.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000143/wf-form4_149764648587584.xml","form_type":"4"}},{"id":4323658,"issuer":{"id":137086,"kind":"organization","name":"ALEXION PHARMACEUTICALS, INC.","symbol":"ALXN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $.0001 per share","published_at":"2017-05-12T18:00:55.000Z","date":"2017-05-10","kind":"grant","acquired":true,"shares":2030,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"RSU's will vest 100% on the 1-year anniversary of the grant date."}],"balance_after":4333,"source":{"system":"sec-edgar","filing":"0000899866-17-000110","document":"wf-form4_149462643941087.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/899866/000089986617000110/wf-form4_149462643941087.xml","form_type":"4"}},{"id":4332175,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-05-05T22:31:39.000Z","date":"2017-05-04","kind":"grant","acquired":true,"shares":1223,"price":245.25,"value":299940.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These restricted stock units shall vest 100% on the earlier of (i) the day before the 2018 Annual General Meeting of Shareholders or (ii) May 4, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":4446,"source":{"system":"sec-edgar","filing":"0001179110-17-006742","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911017006742/edgar.xml","form_type":"4"}},{"id":4332174,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-05-05T22:31:39.000Z","date":"2017-05-03","kind":"tax_withholding","acquired":false,"shares":668,"price":243.76,"value":162831.68,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":3223,"source":{"system":"sec-edgar","filing":"0001179110-17-006742","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000117911017006742/edgar.xml","form_type":"4"}},{"id":4389035,"issuer":{"id":160376,"kind":"organization","name":"DUN & BRADSTREET CORP/NW","symbol":"DNB"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Units - Deferred Compensation","published_at":"2017-03-13T22:42:22.000Z","date":"2017-03-10","kind":"grant","acquired":true,"shares":175.08,"price":40.29,"value":7053.9732,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Phantom stock is reported in units vs. shares in the D&B Common Stock Fund of the issuer's non-employee directors' deferred compensation plan (the \"Plan\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each phantom stock unit entitles the reporting person to a cash payment based on the value on the payout date of the issuer's common stock corresponding to such units.  Based on the $107.80 closing price of the issuer's common stock on the transaction date, one share of common stock corresponds to approximately 2.67 units."},{"field":"shares","element":"transactionShares","label":"F3","text":"Phantom stock is reported in units vs. shares in the D&B Common Stock Fund of the issuer's non-employee directors' deferred compensation plan (the \"Plan\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reporting person may transfer these phantom stock units to alternative investment funds in the Plan beginning three years from the transaction date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These phantom stock units are payable in cash after the reporting person ceases to be a member of the issuer's board of directors."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Phantom stock is reported in units vs. shares in the D&B Common Stock Fund of the issuer's non-employee directors' deferred compensation plan (the \"Plan\")."}],"balance_after":38317.104,"derivative":{"underlying":"Common Stock","underlying_shares":175.08},"source":{"system":"sec-edgar","filing":"0001209191-17-020297","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000120919117020297/doc4.xml","form_type":"4"}},{"id":4389034,"issuer":{"id":160376,"kind":"organization","name":"DUN & BRADSTREET CORP/NW","symbol":"DNB"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-13T22:42:22.000Z","date":"2017-03-10","kind":"grant","acquired":true,"shares":74.6525,"price":107.81,"value":8048.286025,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired pursuant to a dividend reinvestment feature of the issuer's stock incentive plan in connection with restricted stock units held by the reporting person."}],"balance_after":16535.9103,"source":{"system":"sec-edgar","filing":"0001209191-17-020297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000120919117020297/doc4.xml","form_type":"4"}},{"id":4393489,"issuer":{"id":12463,"kind":"organization","name":"HOLOGIC INC","symbol":"HOLX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2017-03-09T21:44:30.000Z","date":"2017-03-08","kind":"grant","acquired":true,"shares":6816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options become exercisable on the date of the 2018 Annual Meeting of Stockholders."}],"balance_after":6816,"derivative":{"exercise_price":41.92,"expiration_date":"2027-03-08","underlying":"Common Stock","underlying_shares":6816},"source":{"system":"sec-edgar","filing":"0001127602-17-011072","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/859737/000112760217011072/form4.xml","form_type":"4"}},{"id":4393488,"issuer":{"id":12463,"kind":"organization","name":"HOLOGIC INC","symbol":"HOLX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true}}],"security":"Restricted Stock Unit Award (Right To Receive)","published_at":"2017-03-09T21:44:30.000Z","date":"2017-03-08","kind":"exercise","acquired":false,"shares":2427,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted Stock Units (RSUs) convert into common stock on a one-for-one basis upon vesting."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units (RSUs) convert into common stock on a one-for-one basis upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs vest and convert into shares of common stock on the date of the 2017 Annual Meeting of Stockholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These RSUs vest and convert into shares of common stock on the date of the 2017 Annual Meeting of Stockholders."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2427},"source":{"system":"sec-edgar","filing":"0001127602-17-011072","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/859737/000112760217011072/form4.xml","form_type":"4"}},{"id":4393487,"issuer":{"id":12463,"kind":"organization","name":"HOLOGIC INC","symbol":"HOLX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-03-09T21:44:30.000Z","date":"2017-03-08","kind":"grant","acquired":true,"shares":2206,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents RSUs which vest on the date of the 2018 Annual Meeting of Stockholders and are settled in shares of common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units (RSUs) convert into common stock on a one-for-one basis upon vesting."}],"balance_after":7633,"source":{"system":"sec-edgar","filing":"0001127602-17-011072","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/859737/000112760217011072/form4.xml","form_type":"4"}},{"id":4393486,"issuer":{"id":12463,"kind":"organization","name":"HOLOGIC INC","symbol":"HOLX"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-03-09T21:44:30.000Z","date":"2017-03-08","kind":"exercise","acquired":true,"shares":2427,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted Stock Units (RSUs) convert into common stock on a one-for-one basis upon vesting."}],"balance_after":5427,"source":{"system":"sec-edgar","filing":"0001127602-17-011072","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/859737/000112760217011072/form4.xml","form_type":"4"}},{"id":4471447,"issuer":{"id":160376,"kind":"organization","name":"DUN & BRADSTREET CORP/NW","symbol":"DNB"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Phantom Stock Units - Deferred Compensation","published_at":"2017-02-02T22:51:24.000Z","date":"2017-01-31","kind":"grant","acquired":true,"shares":728.209,"price":45.73,"value":33300.99757,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Phantom stock is reported in units vs. shares in the D&B Common Stock Fund of the issuer's non-employee directors' deferred compensation plan (the \"Plan\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each phantom stock unit entitles the reporting person to a cash payment based on the value on the payout date of the issuer's common stock corresponding to such units.  Based on the $122.62 closing price of the issuer's common stock on the transaction date, one share of common stock corresponds to approximately 2.68 units."},{"field":"shares","element":"transactionShares","label":"F1","text":"Phantom stock is reported in units vs. shares in the D&B Common Stock Fund of the issuer's non-employee directors' deferred compensation plan (the \"Plan\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person may transfer these phantom stock units to alternative investment funds in the Plan beginning three years from the transaction date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These phantom stock units are payable in cash after the reporting person ceases to be a member of the issuer's board of directors."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Phantom stock is reported in units vs. shares in the D&B Common Stock Fund of the issuer's non-employee directors' deferred compensation plan (the \"Plan\")."}],"balance_after":38142.024,"derivative":{"underlying":"Common Stock","underlying_shares":728.209},"source":{"system":"sec-edgar","filing":"0001209191-17-007237","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000120919117007237/doc4.xml","form_type":"4"}},{"id":4479402,"issuer":{"id":160376,"kind":"organization","name":"DUN & BRADSTREET CORP/NW","symbol":"DNB"},"owners":[{"id":34200,"kind":"person","name":"COUGHLIN CHRISTOPHER J","position":1,"cik":"0001110750","reported_name":"COUGHLIN CHRISTOPHER J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-01-27T23:13:12.000Z","date":"2017-01-26","kind":"exercise","acquired":false,"shares":2086,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":88.04,"exercise_date":"2008-02-08","expiration_date":"2017-02-08","underlying":"Common Stock","underlying_shares":2086},"source":{"system":"sec-edgar","filing":"0001209191-17-006005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1110750/000120919117006005/doc4.xml","form_type":"4"}}],"next_cursor":"2017-01-27T23:13:12.000000Z,4479402"}